Myelosuppressive chemotherapy drugs

Epogen, Procrit, Retacrit Treatment of anemia in patients with nonmyeloid malignancies where anemia is due to effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of 2 additional months of planned chemotherapy

Background: Myelosuppression remains the major dose-limiting toxicity of cancer chemotherapy. The risk of myelotoxicity is associated with the specific drugs, doses and schedule utilized along with patient differences in drug metabolism and tolerance.

Background Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is commonly used to prevent febrile neutropenia (FN), a potentially life-threatening complication, following myelosuppressive chemotherapy. The FDA label for pegfilgrastim specifies that it should not be administered 14 days before or within 24 h of administration of myelosuppressive chemotherapy, precluding

The role of the G-CSFs in patients receiving standard-dose myelosuppressive chemotherapy medication information. It is not meant to be

Some common chemotherapy drugs that may cause myelosuppression are: Fluorouracil: This drug can cause all forms of myelosuppression.

Trilaciclib is a first-of-its-kind prescription medicine that protects against myelosuppression during chemotherapy for SCLC. Learn more.

Patients with Cancer Receiving Myelosuppressive Chemotherapy. Zarxio is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚

Causes of Myelosuppression. The majority of chemotherapy drugs have been associated with myelosuppression. However, different chemo agents affect blood cell

The majority of chemotherapy drugs have been associated with myelosuppression. However, different chemo agents affect blood cell production in different ways. A list of the most common cancer drugs and their myelosuppression characteristics are listed below: Fluorouracil: all forms of myelosuppression; Oxaliplatin: neutropenia and thrombocytopenia